ENDRA Life Sciences Inc. (NDRA)
USD 4.62
(0.87%)
USD 4.62
(0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.78 Million USD | 20.72% |
| 2022 | -12.94 Million USD | -14.21% |
| 2021 | -11 Million USD | 0.11% |
| 2020 | -11.32 Million USD | -4.54% |
| 2019 | -10.83 Million USD | -29.37% |
| 2018 | -9.01 Million USD | -119.62% |
| 2017 | -4.56 Million USD | -413.13% |
| 2016 | -1.72 Million USD | 5.41% |
| 2015 | -1.49 Million USD | 5.82% |
| 2014 | -1.48 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.18 Million USD | 19.89% |
| 2024 Q1 | -2.72 Million USD | -94.52% |
| 2023 FY | - USD | 20.72% |
| 2023 Q1 | -2.86 Million USD | 11.63% |
| 2023 Q4 | -1.39 Million USD | 54.34% |
| 2023 Q3 | -3.05 Million USD | -4.68% |
| 2023 Q2 | -2.92 Million USD | -1.87% |
| 2022 Q2 | -3.51 Million USD | -25.44% |
| 2022 Q3 | -3.35 Million USD | 4.48% |
| 2022 FY | - USD | -14.21% |
| 2022 Q1 | -2.8 Million USD | 8.13% |
| 2022 Q4 | -3.24 Million USD | 3.36% |
| 2021 Q2 | -3.13 Million USD | -24.11% |
| 2021 FY | - USD | 0.11% |
| 2021 Q1 | -2.52 Million USD | -16.04% |
| 2021 Q4 | -3.05 Million USD | -17.49% |
| 2021 Q3 | -2.59 Million USD | 17.27% |
| 2020 Q4 | -2.17 Million USD | 32.74% |
| 2020 FY | - USD | -4.54% |
| 2020 Q3 | -3.24 Million USD | -13.64% |
| 2020 Q2 | -2.85 Million USD | 6.72% |
| 2020 Q1 | -3.05 Million USD | 2.24% |
| 2019 Q2 | -2.3 Million USD | 15.49% |
| 2019 Q1 | -2.72 Million USD | -37.57% |
| 2019 FY | - USD | -29.37% |
| 2019 Q4 | -3.12 Million USD | -17.32% |
| 2019 Q3 | -2.66 Million USD | -15.62% |
| 2018 Q4 | -1.98 Million USD | -12.5% |
| 2018 Q3 | -1.76 Million USD | 2.53% |
| 2018 Q2 | -1.8 Million USD | 35.93% |
| 2018 Q1 | -2.82 Million USD | -23.72% |
| 2018 FY | - USD | -119.62% |
| 2017 FY | - USD | -413.13% |
| 2017 Q1 | 35.91 Thousand USD | -48.28% |
| 2017 Q4 | -2.28 Million USD | -155.82% |
| 2017 Q2 | -1.04 Million USD | -3002.67% |
| 2017 Q3 | -891.72 Thousand USD | 14.47% |
| 2016 Q2 | -478.22 Thousand USD | -36.15% |
| 2016 Q4 | 69.44 Thousand USD | 131.86% |
| 2016 Q1 | -351.25 Thousand USD | 19.38% |
| 2016 Q3 | -217.98 Thousand USD | 54.42% |
| 2016 FY | - USD | 5.41% |
| 2015 FY | - USD | 5.82% |
| 2015 Q4 | -435.71 Thousand USD | 20.63% |
| 2015 Q2 | -116.06 Thousand USD | 39.21% |
| 2015 Q3 | -548.97 Thousand USD | -373.01% |
| 2015 Q1 | -190.91 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 95.419% |
| Prenetics Global Limited | -47.89 Million USD | 79.571% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -480.012% |
| CareDx, Inc | -89.65 Million USD | 89.086% |
| Exact Sciences Corporation | 41.87 Million USD | 123.366% |
| Exagen Inc. | -19.15 Million USD | 48.912% |
| Inotiv, Inc. | -26.5 Million USD | 63.085% |
| Guardant Health, Inc. | -433.3 Million USD | 97.742% |
| Biodesix, Inc. | -37.1 Million USD | 73.628% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -293.729% |
| Precipio, Inc. | -4.31 Million USD | -126.605% |
| iSpecimen Inc. | -9.1 Million USD | -7.481% |
| Natera, Inc. | -383.27 Million USD | 97.447% |
| Aspira Women's Health Inc. | -16.49 Million USD | 40.666% |
| Standard BioTools Inc. | -54.45 Million USD | 82.032% |
| 23andMe Holding Co. | -291.87 Million USD | 96.648% |
| Castle Biosciences, Inc. | -45.02 Million USD | 78.268% |
| Personalis, Inc. | -96.8 Million USD | 89.892% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 91.677% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -2.02% |
| OpGen, Inc. | -29.51 Million USD | 66.844% |
| T2 Biosystems, Inc. | -43.87 Million USD | 77.698% |
| Myriad Genetics, Inc. | -67.8 Million USD | 85.568% |
| ICON Public Limited Company | 1.63 Billion USD | 100.6% |
| NeoGenomics, Inc. | -17.6 Million USD | 44.427% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -480.012% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.804% |
| RadNet, Inc. | 292.78 Million USD | 103.342% |
| MDxHealth SA | -30.46 Million USD | 67.885% |
| Psychemedics Corporation | -251 Thousand USD | -3798.328% |
| Illumina, Inc. | -608 Million USD | 98.391% |
| Check-Cap Ltd. | -17.64 Million USD | 44.559% |
| Twist Bioscience Corporation | -176.7 Million USD | 94.463% |
| DarioHealth Corp. | -53.49 Million USD | 81.709% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 78.981% |
| Sera Prognostics, Inc. | -35.28 Million USD | 72.271% |
| OPKO Health, Inc. | -65.51 Million USD | 85.065% |
| Medpace Holdings, Inc. | 363.15 Million USD | 102.694% |
| Neogen Corporation | 182.59 Million USD | 105.359% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -11.056% |
| Prenetics Global Limited | -47.89 Million USD | 79.571% |
| Mainz Biomed B.V. | -25.01 Million USD | 60.878% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -28.253% |
| Trinity Biotech plc | -24.09 Million USD | 59.396% |
| Neuronetics, Inc. | -22.75 Million USD | 57.007% |
| Sotera Health Company | 514.14 Million USD | 101.903% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -28.253% |